SAM
TVRD

Silvercrest Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Silvercrest Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$321K Hold
101,034
– – ﹤0.01% 757
2025
Q4 		$434K Buy
101,034
+78,668
+352% +$705K ﹤0.01% 738
2025
Q3 		$872K Buy
+22,366
New +$637K 0.01% 627

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Silvercrest Asset Management's TVRD Position: Q1 2026 in Review

Silvercrest Asset Management held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 101,034 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #757.

Silvercrest Asset Management first reported a position in TVRD in Q3 2025 and has held it in 3 quarters since. The position peaked at $872K in Q3 2025. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Silvercrest Asset Management held 101,034 shares of Tvardi Therapeutics worth $321K as of Q1 2026.
  • Silvercrest Asset Management left its Tvardi Therapeutics share count unchanged in Q1 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q1 2026, its #757 holding.
  • Silvercrest Asset Management first reported a position in Tvardi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Silvercrest Asset Management's Tvardi Therapeutics position peaked at $872K in Q3 2025.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.